At the recent Conference on Retroviruses and Opportunistic Infections, researchers presented data about 5 new anti-HIV compounds in development.
In a small cross-sectional study researchers found a link between the use of integrase inhibitors and the presence of low testosterone, but they may have inadvertently arrived at this conclusion.
Two cohort studies presented at CROI 2017 showed a higher risk of IRIS with integrase inhibitor-based ART than with other regimens.
New research shows that it may be possible to identify many latently infected CD4 T cells due to expression of a particular cell surface protein.
One injection of long-acting cabotegravir (CAB LA) protected 21 of 24 macaques from intravenous challenge with simian immunodeficiency virus (SIV).
Giving monkeys two powerful anti-HIV antibodies immediately after infection with an HIV-like virus enabled the immune systems of some of the animals to control the virus long after the antibodies were gone.
Three broadly neutralizing antibodies in an HIV-positive person may explain how this individual controlled HIV for 30 years without antiretroviral therapy.
A first-in-class HIV-1 capsid inhibitor interrupts replication at two steps of the viral lifecycle and has pharmacokinetic properties that may permit once-monthly or less frequent dosing.
Two new monoclonal antibodies demonstrated success in helping people living with HIV suppress their viral loads to undetectable levels.
A new analysis reports that HIV-positive women in clinical trials in sub-Saharan Africa are likely to get pregnant as often as those receiving care outside of research settings.